


An Update on African AIDS Vaccine Program (AAVP)



Established 2000



World Health
Organization



UNAIDS
JOINT UNITED NATIONS PROGRAMME ON HIV/AIDS

UNHCR
UNICEF
WFP
UNDP
UNFPA
UNODC
ILO
UNESCO
WHO
WORLD BANK


Initiation of AAVP

The Nairobi meeting June 2000

Two major outcomes:

- **The Nairobi Declaration:**
An African Appeal for an HIV Vaccine.
- **The African AIDS Vaccine Strategy:**
An outline describing vision, goals, principles, milestones and activities framework.

AAVP was adopted by the African Heads of States at the HIV/AIDS, TB and Malaria summit in Abuja in April 2001 (Abuja declaration). Endorsed by ECOWAS, SADEC & NEPAD



The AAVP Vision and Mission

Vision: "An AIDS-Free Africa through an Effective Vaccine"

Mission: "The AAVP is a network of African HIV vaccine stakeholders, committed to HIV vaccine development for Africa, through research, advocacy, partnership, and contribution to capacity strengthening and policy development."

Objectives of the AAVP

- To develop advocacy strategies & communication tools on HIV vaccines
- To network people and institutions on HIV vaccines
- To promote the development of appropriate candidate vaccines for Africa
- To facilitate the preparation for clinical trials through capacity building
- To develop plans for future access in Africa

The Reasons for the Development of the New AAVP Strategic Plan

- The AAVP has been successful in a number of areas
- There is a changed global environment
- Support from stakeholders for continued activities and changes
- Great opportunity to take a leadership role
- Need for structural and functional changes


The AAVP Identity

- **African Network located in Africa and led by African leaders representing various communities involved in HIV vaccine R&D**
- **A central platform ensuring adequate support, global representation and equal partnership role of African communities in the global HIV vaccine R&D efforts**
- **Contributes to creation of a supportive normative environment and meaningful capacity in African countries for the conduct of all phases of HIV vaccine trials in Africa at the highest scientific and ethical standards**
- **Diversified structure of collaborating institutions across the continent with extensive expertise in various areas of work and their ability to spread this expertise base to other relevant partners**

The AAVP Principles for Partnerships and Collaboration

- The AAVP central role is to be a partnership-based network with external and internal stakeholders, coherent with the goals of the Global HIV Vaccine Enterprise
- Involvement of all relevant stakeholders and development agencies, including the non-HIV, poverty diseases targeted programmes, based on open collaboration and complementarity
- Sharing its resources, capacities, experiences and information
- Alignment with multiple global initiatives for funding opportunities

The Former AAVP Structure




AAVP Structure:

Principles for the proposed new structure

1. Take into account the recently conducted external review.
2. Reflect the outcomes of the consultation process (internal and external) conducted as part of this strategy development process.
3. Structured on the basis of what is thought to give the greatest operational and functional efficiency and professional approach.
4. The type of proposed AAVP work should influence the structure.
5. The magnitude of the planned efforts should influence the structure.
6. Ensure transparency and accountability.
7. Take into account the realities of the new funding environment.

The AAVP Structure (5 year strategic plan 2006-2011)



* National strategic planning managed by AAVP secretariat as one of the activities

AAVP Framework for it's 5 year Strategic Plan (2006-2011)

AAVP Work Areas

AAVP Strategic Directions

Country-based strategic planning	Capacity Strengthening	Advocacy	Policy Development	Community Involvement	Networking
Biomedical research					
Communication & media					
Regulatory issues					
Ethics, law and human rights					

AAVP Collaborating Centers: Progress Report

Biomedical research	Professor Souleymane MBoup Senegal
Communication & media	ACE Communication and Media, Kenya
Regulatory issues	
Ethics, law and human rights	Dr. Doug Wassenaar S. Africa

AAVP Biomedical Collaborating Centre for HIV/AIDS vaccine research and development, and clinical trials in the African region

AAVP BMCC Objectives (1)

To evaluate and identify needs and priorities

- assessment which will be done using a questionnaire
- Collection of information from partners
- Exchanges of experiences from experts, countries conducting trials and consensus workshop.

AAVP BMCC Objectives (2)

To initiate and develop networking and exchange of expertise

- between countries, institutions, initiatives and partners
- strengthening of existing networks such as the AARN
- collaboration with other institutions.

AAVP BMCC Objectives (3)

Strengthen capacity building :

- workshops, short and long term training focusing on laboratory techniques
 - current technologies and approaches to standardise measurements of vaccine-induced immune responses,
 - immune correlates of HIV infection and pathogenesis,
 - monitor viral strains circulating in populations in Africa
 - sample preparation and tracking,
- repository management,
- QA/QC etc.

AAVP BMCC Objectives (4)

● To implement a database on clinical trials in the region :

- updated list of all researchers and stakeholders on HIV/AIDS vaccine research and development on the continent
- available techniques and tools needed to monitor immune and virological responses
- physiological normal values for African population
- updated molecular epidemiology of HIV strains circulating in the region


AAVP BMCC

- Reinforce partnership with institutions, initiatives and universities involved in the area of HIV/AIDS vaccine.
- Virtual centre with the co-ordinating centre in Senegal and affiliated centres in Uganda and South Africa.

National AIDS Vaccine Plans

- January 2001 Nigeria
- July 2001 Tanzania
- October 2001 Zambia
- September 2002 Cote D'Ivoire
- October 2002 Ethiopia
- November 2002 Cameroon
- September 2003 Uganda (update)
- March 2006 Uganda (update)
- July 2004 Kenya
- September 2004 Tanzania (update)
- December 2004 Botswana
- March 2005 Kenya

Developing the Nigerian National Vaccine Plan



Coumba Tourec from WHO/UNAIDS facilitating the workshop in Abuja to develop Nigerian HIV vaccine Plan.
April 2000



AAVP Forums

A Highly visibility meeting bringing together all partners, including African and international scientists, research agencies and donors

June 2002: The First AAVP Forum was launched in Cape Town, South Africa
Major recommendation: Develop strategies and plans to support the on-going efforts to implement multiple HIV vaccine trial sites in Africa.

June 2003: 2nd forum in Addis Ababa, Ethiopia
Major recommendation: Need the development of ethical, legal and regulatory frameworks in support of the development of HIV vaccine trial sites

October 2005: 3rd forum in Yaoundé, Cameroon
Major recommendation: **YAOUNDE STATEMENT** - Need to better define Africa's role and contribution to the global efforts for the development of safe, effective and affordable HIV vaccines for African countries,.

November 28th -30th 2007: 4th forum in Abuja, Nigeria
Major recommendation: ??

Potential Areas of Collaboration

- Implementation of National Vaccine Plans
- Work together on advocacy, policy and community issues
- Human Resources Capacity building Training fellowships
- Support capacity building (GCP, regulatory, ethics, scientific)
- Site development including support of other trials e.g. malaria or TB which could have benefit to HIV vaccine trials
- Support targeted research via institutional and regional collaboration (new AAVP collaborating centers):

http://www.who.int/vaccine_research/diseases/hiv/aavp/aavp_full_applications/en/index.html

Funding

- CIDA Canada
- SIDA/SAREC Sweden
- WHO/UNAIDS
- Netherlands
- IAVI
- CDC, NIH, ANRS, DoD, SAAVI (Co-sponsor specific activities)

Acknowledgement

Steering Committee Members:

Pontiano Kaleebu (Uganda)– **chair**
Alash'le Abimiku (Nigeria/USA) - **vice-chair**
John Nkengasong (Cameron/USA)
Dawit Wolday (Ethiopia)
Shenaaz El Halabi (Botswana)
Sinata Koulla-Shiro (Cameroun)
Coumba Toure Kane (Senegal)

WHO AAVP Secretariat

Marie-Paule Kieny
Saladin Osmanov
Coumba Touré
Guy Michel Gershly Damet
Raymond Hutubessy

AIDS Vaccine Family and AAVP Sponsors